Caris Life Sciences vs CareDx
CAI and CDNA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAI and CDNA compare
Caris Life Sciences is the larger company, worth 1.6 times as much as CareDx ($6.5B against $4.1B).
Caris Life Sciences grew revenue faster over the last twelve months (61.5% versus 38.9% for CareDx).
CareDx keeps more of each dollar of sales as profit, with a net margin of 25.9% compared with 9.2% at Caris Life Sciences.
CareDx scores higher on the StockData Score (12 against 7 for Caris Life Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAI | CDNA |
|---|---|---|
| Size and price | ||
| Market cap | $6.5B | $4.1B |
| Share price | $23.04 | $77.88 |
| Change, 1 year | −7.0% | 377% |
| Change, 5 years | – | 81.1% |
| Beta (5Y) | 2.21 | 1.51 |
| Employees | 1,846 | 765 |
| StockData Score | ||
| Total score | 7 | 12 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 32.6× |
| P/S | 6.2× (better) | 8.2× |
| P/B | 10.2× | 8.8× (better) |
| EV/EBITDA | 41.9× | 28.6× (better) |
| P/FCF | 225× | – |
| FCF yield | 0.44% | – |
| Fair value | $10.40 | $58.77 |
| Margin of safety | −121% | −32.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 61.5% (better) | 38.9% |
| Revenue growth, 5Y average | – | 14.6% |
| Net income growth (TTM) | – | 82.6% |
| Profitability | ||
| Operating margin | 13.4% | 23.4% (better) |
| Net margin | 9.2% | 25.9% (better) |
| FCF margin | 2.8% | – |
| Return on equity | 17.2% | 33.0% (better) |
| Return on invested capital | 26.8% | 69.8% (better) |
| Financial health | ||
| Debt / equity | 0.61 (better) | 0.00 |
| Net debt / EBITDA | 1.79 | – |
| Interest coverage | 3.3× | – |
| Current ratio | 6.71 (better) | 2.31 |
| Altman Z-score | 5.58 | 14.77 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | 0.48% | – |
| Shareholder yield | 0.48% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 54.5% | 102% |
| Held by insiders | 64.1% | 4.8% |
| Insider net buying, 12 months | −$27.4M | −$18.4M (better) |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 11.3% | 14.4% |
Go deeper
- CAI stock overview
- CAI income statement
- CAI valuation and score
- CDNA stock overview
- CDNA income statement
- CDNA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.